Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Baxter
Fish and Richardson
Julphar
Dow
Merck
AstraZeneca
Harvard Business School

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,726,918

« Back to Dashboard

Which drugs does patent 6,726,918 protect, and when does it expire?

Patent 6,726,918 protects OZURDEX and is included in one NDA.

This patent has sixteen patent family members in twelve countries.
Summary for Patent: 6,726,918
Title: Methods for treating inflammation-mediated conditions of the eye
Abstract:Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos Hills, CA)
Assignee: Oculex Pharmaceuticals, Inc. (Sunnyvale, CA)
Application Number:09/693,008
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 6,726,918

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF MACULAR EDEMA ➤ Try a Free Trial
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF UVEITIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,726,918

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,012,437 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Try a Free Trial
8,063,031 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Try a Free Trial
9,775,849 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Try a Free Trial
8,242,099 Implants and methods for treating inflammation-mediated conditions of the eye ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,726,918

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029567 ➤ Try a Free Trial
Austria 339185 ➤ Try a Free Trial
Australia 2001273166 ➤ Try a Free Trial
Australia 2005246995 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Farmers Insurance
Chubb
Healthtrust
Fuji
Moodys
Federal Trade Commission
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.